雷珠单抗治疗湿性年龄相关性黄斑变性的视力改善与黄斑形态学变化相关性分析

目的 分析雷珠单抗治疗湿性年龄相关性黄斑变性的视力改善和黄斑形态学变化之间的相关性。方法 选取2014年1月~2016年2月在西安交通大学第一附属医院行雷珠单抗治疗的湿性年龄相关性黄斑变性患者43例（1眼/例）。观察治疗前后最佳矫正视力（BCVA）、黄斑中心凹厚度（CMT）及黄斑病变面积。分析视力改善与黄斑形态学变化之间的相关性。结果 治疗3个月后，BCVA升高字母数（8.93±5.70）个，CMT下降（115.35±56.24）μm，黄斑病变面积减少（2.04±0.65）mm2。治疗3个月后，BCVA变化与CMT变化之间无相关性（r=-0.170，P＞0.05）；BCVA变化与黄斑病变面积改变之间无相关性（r=-0.101，P＞0.05）。结论 雷珠单抗治疗湿性AMD具有较好疗效，提高患者视力，改善黄斑形态学，视力改善与黄斑形态学变化之间无相关性。

Correlation between Visual Acuity Improvement and Morphological Changes of Macular in Treatment of Wet Age-related Macular Degeneration with Ranibizumab

Objective To retrospectively analyze the correlations between visual acuity and macular morphology after ranibizumab therapy for the wet age-related macular degeneration. Methods From January 2014 to February 2016, 43 patients (1 eye/case) of wet age-related macular degeneration treated with ranibizumab in the First Affiliated Hospital of Xi'an Jiaotong University were selected. The best corrected visual acuity (BCVA), macular foveal thickness (CMT) and macular degeneration area were observed before and after treatment. Analyze the correlation between visual acuity improvement and morphological changes of the macula. Results After 3 months of treatment, the number of letters in BCVA increased (8.93±5.70), the CMT decreased (115.35±56.24)μm, and the area of macular lesion decreased (2.04±0.65) mm2. There was no correlation between BCVA changes and CMT changes after 3 months of treatment (r=-0.170, P>0.05); there was no correlation between BCVA changes and macular lesions (r=-0.101, P>0.05). Conclusion Ralmuzumab has a good effect in the treatment of wet AMD, improving vision and improving macular morphology, and there is no correlation between visual acuity improvement and macular morphological changes.